365 related articles for article (PubMed ID: 24401529)
1. Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors.
Michl M; Haug AR; Jakobs TF; Paprottka P; Hoffmann RT; Bartenstein P; Boeck S; Haas M; Laubender RP; Heinemann V
Oncology; 2014; 86(1):24-32. PubMed ID: 24401529
[TBL] [Abstract][Full Text] [Related]
2. Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis.
Kim AY; Frantz S; Brower J; Akhter N
J Vasc Interv Radiol; 2019 Mar; 30(3):298-304.e2. PubMed ID: 30819469
[TBL] [Abstract][Full Text] [Related]
3. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.
Paprottka PM; Hoffmann RT; Haug A; Sommer WH; Raessler F; Trumm CG; Schmidt GP; Ashoori N; Reiser MF; Jakobs TF
Cardiovasc Intervent Radiol; 2012 Apr; 35(2):334-42. PubMed ID: 21847708
[TBL] [Abstract][Full Text] [Related]
4. Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver.
Abdelmaksoud MH; Louie JD; Hwang GL; Kothary N; Minor DR; Sze DY
J Vasc Interv Radiol; 2012 Mar; 23(3):323-30.e1. PubMed ID: 22277275
[TBL] [Abstract][Full Text] [Related]
5. Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience.
Memon K; Kuzel TM; Vouche M; Atassi R; Lewandowski RJ; Salem R
Melanoma Res; 2014 Jun; 24(3):244-51. PubMed ID: 24638152
[TBL] [Abstract][Full Text] [Related]
6. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
8. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.
Sangro B; Carpanese L; Cianni R; Golfieri R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Van Buskirk M; Bilbao JI; Ettorre GM; Salvatori R; Giampalma E; Geatti O; Wilhelm K; Hoffmann RT; Izzo F; Iñarrairaegui M; Maini CL; Urigo C; Cappelli A; Vit A; Ahmadzadehfar H; Jakobs TF; Lastoria S;
Hepatology; 2011 Sep; 54(3):868-78. PubMed ID: 21618574
[TBL] [Abstract][Full Text] [Related]
9. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases.
Seidensticker R; Denecke T; Kraus P; Seidensticker M; Mohnike K; Fahlke J; Kettner E; Hildebrandt B; Dudeck O; Pech M; Amthauer H; Ricke J
Cardiovasc Intervent Radiol; 2012 Oct; 35(5):1066-73. PubMed ID: 21800231
[TBL] [Abstract][Full Text] [Related]
10. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.
Bester L; Meteling B; Pocock N; Pavlakis N; Chua TC; Saxena A; Morris DL
J Vasc Interv Radiol; 2012 Jan; 23(1):96-105. PubMed ID: 22079516
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
Hendlisz A; Van den Eynde M; Peeters M; Maleux G; Lambert B; Vannoote J; De Keukeleire K; Verslype C; Defreyne L; Van Cutsem E; Delatte P; Delaunoit T; Personeni N; Paesmans M; Van Laethem JL; Flamen P
J Clin Oncol; 2010 Aug; 28(23):3687-94. PubMed ID: 20567019
[TBL] [Abstract][Full Text] [Related]
12. Yttrium-90 radioembolization in patients with unresectable liver metastases: determining the factors that lead to treatment efficacy.
Gunduz S; Ozgur O; Bozcuk H; Coşkun HS; Ozdogan M; Erkilic M; Sindel T; Yldlzs A; Ylmaz S; Boz A; Aydin F; Karayalçin B; Savas B
Hepatogastroenterology; 2014 Sep; 61(134):1529-34. PubMed ID: 25436337
[TBL] [Abstract][Full Text] [Related]
13. Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer.
Michl M; Lehner S; Paprottka PM; Ilhan H; Bartenstein P; Heinemann V; Boeck S; Albert NL; Fendler WP
J Nucl Med; 2016 Mar; 57(3):355-60. PubMed ID: 26609176
[TBL] [Abstract][Full Text] [Related]
14. 90Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study.
Hickey R; Lewandowski RJ; Prudhomme T; Ehrenwald E; Baigorri B; Critchfield J; Kallini J; Gabr A; Gorodetski B; Geschwind JF; Abbott A; Shridhar R; White SB; Rilling WS; Boyer B; Kauffman S; Kwan S; Padia SA; Gates VL; Mulcahy M; Kircher S; Nimeiri H; Benson AB; Salem R
J Nucl Med; 2016 May; 57(5):665-71. PubMed ID: 26635340
[TBL] [Abstract][Full Text] [Related]
15. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy.
Ezziddin S; Meyer C; Kahancova S; Haslerud T; Willinek W; Wilhelm K; Biersack HJ; Ahmadzadehfar H
J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059
[TBL] [Abstract][Full Text] [Related]
16. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.
Kennedy AS; Dezarn WA; McNeillie P; Coldwell D; Nutting C; Carter D; Murthy R; Rose S; Warner RR; Liu D; Palmedo H; Overton C; Jones B; Salem R
Am J Clin Oncol; 2008 Jun; 31(3):271-9. PubMed ID: 18525307
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization.
Fan KY; Wild AT; Halappa VG; Kumar R; Ellsworth S; Ziegler M; Garg T; Rosati LM; Su Z; Hacker-Prietz A; Pawlik TM; Cosgrove DP; Hong KK; Kamel IR; Geschwind JF; Herman JM
Contemp Clin Trials; 2016 Sep; 50():143-9. PubMed ID: 27520932
[TBL] [Abstract][Full Text] [Related]
18. Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study.
Benson AB; Geschwind JF; Mulcahy MF; Rilling W; Siskin G; Wiseman G; Cunningham J; Houghton B; Ross M; Memon K; Andrews J; Fleming CJ; Herman J; Nimeiri H; Lewandowski RJ; Salem R
Eur J Cancer; 2013 Oct; 49(15):3122-30. PubMed ID: 23777743
[TBL] [Abstract][Full Text] [Related]
19. Transarterial Radioembolization Treatment of Pancreatic Cancer Patients with Liver-Dominant Metastatic Disease Using Yttrium-90 Glass Microspheres: A Single-Institution Retrospective Study.
Kayaleh R; Krzyston H; Rishi A; Naziri J; Frakes J; Choi J; El-Haddad G; Parikh N; Sweeney J; Kis B
J Vasc Interv Radiol; 2020 Jul; 31(7):1060-1068. PubMed ID: 32534978
[TBL] [Abstract][Full Text] [Related]
20. Impact of prior hepatectomy on the safety and efficacy of radioembolization with yttrium-90 microspheres for patients with unresectable liver tumors.
Bester L; Feitelson S; Milner B; Chua TC; Morris DL
Am J Clin Oncol; 2014 Oct; 37(5):454-60. PubMed ID: 23388564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]